OCUL — Ocular Therapeutix Inc

Ocular Therapeutix Inc (OCUL) is a biotechnology company listed on NASDAQ. It is led by Pravin U. Dugel M.D., based in 15 Crosby Drive, Bedford, MA, United States, 01730, with about 274 employees. Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and in Phase 1 clinical trials for the treatment of non-proliferative diabetic retinopathy; PAXTRAVA, a travoprost intracameral hydrogel, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and PAXTRAVA. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Latest reported OCUL revenue for 2025-09-30 was $14.5M. Net income was -$201.3M. Revenue was up 8.1% from 2025-06-30 to 2025-09-30. OCUL currently screens at market cap $1.76B.

Use this OCUL page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the OCUL quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the OCUL SEC filings page. Lician reads the product cache first so this HTML stays unique to Ocular Therapeutix Inc even when a live quote feed is slow.